Research programme: protein tyrosine kinase inhibitors - ARIAD

Drug Profile

Research programme: protein tyrosine kinase inhibitors - ARIAD

Alternative Names: AP 23864; AP 23994; AP 24163; Inhibitor A; Oncogenic kinase inhibitors - ARIAD

Latest Information Update: 17 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Protein kinase inhibitors; Protein tyrosine kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Solid tumours

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 13 Jan 2015 Preclinical trials in Solid tumours in USA (PO)
  • 26 Aug 2010 Preclinical pharmacodynamics and pharmacokinetics data presented at the 240th American Chemical Society National Meeting (240th-ACS-2010)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top